InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Alzamend Neuro, Inc.

ALZN Clue Score27
United States Fiscal year ends April CIK 0001677077
$1.34 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.34 −45.97% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 15 Jun 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2020Operating income−4.4Net income−4.4Fiscal year 2021Operating income−5.0Net income−5.0Fiscal year 2022Operating income−12.3Net income−12.4EPS, diluted−0.14Fiscal year 2023Operating income−14.9Net income−14.9EPS, diluted−22.89Fiscal year 2024Operating income−9.9Net income−9.9EPS, diluted−132.33Fiscal year 2025Operating income−4.5Net income−4.5EPS, diluted−11.32Fiscal year 2026Operating income−8.8Net income−8.8EPS, diluted−2.63
FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating income −4.4 −5.0 −12.3 −14.9 −9.9 −4.5 −8.8
Net income −4.4 −5.0 −12.4 −14.9 −9.9 −4.5 −8.8
Growth
EPS, diluted n/a n/a −0.14 −22.89 −132.33 −11.32 −2.63

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2020Operating cash flow−2.3Fiscal year 2021Operating cash flow−2.7Fiscal year 2022Operating cash flow−6.6Fiscal year 2023Operating cash flow−8.9Fiscal year 2024Operating cash flow−8.3Fiscal year 2025Operating cash flow−6.6Fiscal year 2026Operating cash flow−8.1
FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −2.3 −2.7 −6.6 −8.9 −8.3 −6.6 −8.1

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash0.1Shareholders’ equity0.8Fiscal year 2021Cash1.9Shareholders’ equity2.0Fiscal year 2022Cash14.1Shareholders’ equity13.4Fiscal year 2023Cash5.1Shareholders’ equity3.0Fiscal year 2024Cash0.4Shareholders’ equity−2.6Fiscal year 2025Cash3.9Shareholders’ equity4.0Fiscal year 2026Cash0.7Shareholders’ equity0.7
FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash 0.1 1.9 14.1 5.1 0.4 3.9 0.7
Shareholders’ equity 0.8 2.0 13.4 3.0 −2.6 4.0 0.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending April, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 30 Apr 2020 FY2021 30 Apr 2021 FY2022 30 Apr 2022 FY2023† 30 Apr 2023 FY2024† 30 Apr 2024 FY2025† 30 Apr 2025 FY2026† 30 Apr 2026
Assets
0.1 1.9 14.1 5.1 0.4 3.9 0.7
n/a n/a 0.1 0.1 0.2 0.4 0.3
1.8 2.9 14.5 5.9 0.6 4.6 2.1
Growth +60.6% +398.4% −59.2% −89.3% +628.8% −54.8%
Liabilities
n/a 0.9 1.2 2.9 3.2 0.6 1.3
Equity
−11.8 −16.8 −29.2 −44.1 −54.0 −58.5 −67.3
0.8 2.0 13.4 3.0 −2.6 4.0 0.7
Growth +145.0% +563.3% −77.2% −185.2% −81.5%
Per share and net cash
64.8 67.4 95.5 0.6 0.1 0.8 4.3
calc 0.01 0.03 0.14 4.71 −33.94 5.10 0.17

† The diluted share count jumps at 2023 and 2024 and 2025 and 2026, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how.